Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical company Shire has demonstrated that adults with attention deficit hyperactivity disorder experienced significant improvements in symptom control, within one week of treatment with once-daily Vyvanse, the first prodrug stimulant.
Subscribe to our email newsletter
In a double-blind, placebo-controlled, four-week study with dose escalations in 414 adults aged 18 to 55 years, treatment with Vyvanse showed reduction in ADHD-RS-IV scores ranging from 16.2 to 18.6 points, as measured from the study’s start to end, the primary endpoint of this study.
The clinical global impressions-improvement (CGI-I) scale, found that the percentage of subjects taking Vyvanse rated improved on the CGI-I scale ranged from 57% to 61% across all doses and was significantly greater than placebo.
Vyvanse is a therapeutically inactive prodrug, in which d-amphetamine
is covalently bonded to l-lysine, and after oral ingestion it is converted
to pharmacologically active d-amphetamine.
A supplemental new drug application for Vyvanse for the treatment of ADHD in adults is currently under review by the FDA. Vyvanse is currently approved in the US for the treatment of ADHD in children aged six to 12 years.